SPS
NTLA icon

Susquehanna Portfolio Strategies’s Intellia Therapeutics NTLA Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Buy
209,461
+95,557
+84% +$1.34M 0.06% 348
2026
Q1 		$1.46M Sell
113,904
-18,743
-14% -$239K 0.02% 565
2025
Q4 		$1.19M Hold
132,647
– – 0.02% 614
2025
Q3 		$2.29M Hold
132,647
– – 0.04% 485
2025
Q2 		$1.24M Buy
132,647
+109,340
+469% +$898K 0.03% 471
2025
Q1 		$166K Buy
+23,307
New +$235K 0.07% 134

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Susquehanna Portfolio Strategies's NTLA Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Intellia Therapeutics (NTLA) stake by 84% in Q2 2026, buying an estimated $1.34M and bringing the position to 209,461 shares worth $3.54M. The position accounts for 0.06% of the portfolio, ranked #348.

Susquehanna Portfolio Strategies first reported a position in NTLA in Q1 2025 and has held it in 6 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Susquehanna Portfolio Strategies held 209,461 shares of Intellia Therapeutics worth $3.54M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 95,557 Intellia Therapeutics shares in Q2 2026, an estimated $1.34M.
  • Intellia Therapeutics made up 0.06% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #348 holding.
  • Susquehanna Portfolio Strategies first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.